Glucose lowering and the kidney: are all drug classes equal?

Lancet Diabetes Endocrinol. 2018 Nov;6(11):835-837. doi: 10.1016/S2213-8587(18)30291-2. Epub 2018 Oct 3.

Authors

Muh Geot Wong¹, Meg Jardine¹, Vlado Perkovic²

Affiliations

¹ The George Institute for Global Health, UNSW Sydney, Sydney, NSW 2042, Australia.
² The George Institute for Global Health, UNSW Sydney, Sydney, NSW 2042, Australia. Electronic address: [email protected].

PMID: 30292590
DOI: 10.1016/S2213-8587(18)30291-2

No abstract available

MeSH terms

Blood Glucose
Diabetes Mellitus, Type 2 / drug therapy*
Diabetic Nephropathies / chemically induced
Diabetic Nephropathies / prevention & control*
Dipeptidyl-Peptidase IV Inhibitors / therapeutic use
Glucagon-Like Peptide-1 Receptor Agonists
Humans
Hypoglycemic Agents / adverse effects
Hypoglycemic Agents / therapeutic use*
Sodium-Glucose Transporter 2 Inhibitors / therapeutic use
Treatment Outcome

Substances

Blood Glucose
Dipeptidyl-Peptidase IV Inhibitors
Hypoglycemic Agents
Sodium-Glucose Transporter 2 Inhibitors
Glucagon-Like Peptide-1 Receptor Agonists